Key result
Rivaroxaban therapy achieved clinical response with remission of both pain and ulceration in 82.2% of patients with livedoid vasculopathy.
Why the study?
Does rivaroxaban improve pain and ulceration in patients with livedoid vasculopathy?
Systematic Review (n=73)
Does rivaroxaban improve pain and ulceration in patients with livedoid vasculopathy?
Rivaroxaban appears to be an effective and well-tolerated treatment for livedoid vasculopathy, achieving high rates of pain and ulceration remission.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban for livedoid vasculopathy remission; extends case-series data but leaves open need for RCTs before practice change.
Rivaroxaban is a direct inhibitor of activated coagulation factor X and competitively targets factor Xa via reversible binding. We conducted a systematic review of the efficacy and safety of rivaroxaban for treatment of livedoid vasculopathy (LV) by searching the PubMed, Cochrane and Embase databases. A total of 22 articles and 1 registered clinical trial were identified in the search of which 13 were included. The studies included 73 LV patients receiving rivaroxaban therapy (10-20 mg per day). Overall, 60 patients (82.2%) had responses to therapy, achieving remission of both pain and ulceration. Few adverse effects were observed. Thus, the consensus of the clinical evidence is that rivaroxaban is a well-tolerated and effective treatment for LV. However, this still needs to be confirmed by large prospective and/or case control studies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2021) conducted a systematic review in Livedoid vasculopathy (n=73). Rivaroxaban was evaluated on Response to therapy, achieving remission of both pain and ulceration. Rivaroxaban therapy achieved clinical response with remission of both pain and ulceration in 82.2% of patients with livedoid vasculopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: